TeraWulf is entering the final stretch of September with a striking divergence: the stock is up 20% on the week to $17.33, five analysts have initiated coverage in the past month, and yet short sellers are holding their ground at one of the most elevated levels in the sector.
Short interest is the central tension here. Bears have staked out 28.3% of the free float — roughly 118.6 million shares — and barely flinched despite the recent rally. The week-on-week change was just -1%, meaning the squeeze pressure has not materially dislodged the short base even as the stock posted a 20% gain. The month-on-month direction is actually higher, with SI up 6.5% over 30 days, suggesting the most recent leg of the rally attracted fresh short sellers rather than triggering a wave of covering. That is a large and stubborn position. The ORTEX short score of 68.3 — near the top of the recent range — reflects the elevated structural weight of that short base.
The borrow market tells a more relaxed story, and that relaxation is recent and significant. Availability has loosened sharply, rising from around 60% at end-August to 125.8% now — meaning there are roughly five shares available to borrow for every four already lent out. Cost to borrow has fallen 24% over the past month to just 0.56%, effectively the cheapest it has been all year. The lending market, in other words, is well-supplied. Shorts are not under pressure from the borrow side; new entrants can add positions without paying a premium. That combination — heavy existing short interest plus cheap and available borrow — is not typically how a squeeze sets up. Options pricing reinforces the bullish lean in the market: the put/call ratio of 0.34 is nearly 1.7 standard deviations below its 20-day average, indicating that call demand is running well ahead of put buying. Options traders are positioned for more upside, even as short sellers stay anchored.
The analyst community has moved decisively in one direction over the past two weeks. Five separate initiations have landed since early September — UBS at Buy with a $24 target, Wells Fargo at Overweight with $30, Rothschild at a more cautious Neutral with $15, Freedom Capital Markets at Buy with $19, and William Blair at Outperform without a published target. The consensus sits at Buy across 17 analysts, with a mean price target of $33.85 — roughly 95% above the current price. Morgan Stanley, which carries the most bullish published target at $62.50, did trim from $72 in August while keeping its Overweight rating. The bull case centers on TeraWulf's pivot to AI infrastructure — a 20-year Kentucky site lease that management says could generate up to $19 billion in revenue, alongside partnerships in high-performance computing. The bear case is more structural: governance concerns, executive compensation questions, regulatory risk, and continued profitability challenges in a company still posting negative earnings. The EV/EBITDA multiple of 26.4x has compressed roughly 9% over 30 days, consistent with a stock that has re-rated faster than underlying earnings estimates have moved.
Insider activity over the past 90 days has been net negative in dollar terms — roughly $8.8 million sold against modest buying — but the picture is nuanced. CEO Paul Prager sold $2.35 million of stock on August 27 under a pre-arranged 10b5-1 plan, which is a scheduled, non-discretionary sale and carries less signal weight than an open-market decision. Two directors sold in September, including Catherine Motz ($998k on September 8) and Walter Carter ($1.98 million on August 31), both discretionary open-market transactions. On the other side, director Michael Bucella has been a consistent buyer, making three separate open-market purchases totalling around $190k across August and September. The net read is a company where C-suite selling is largely plan-driven, board-level selling is real but not outsized, and one director is actively adding exposure in the $14–17 range. One notable item on the 13D register: CEO Prager filed a Schedule 13D/A disclosing a 7% stake as of end-2024. His holdings have since been reported higher in subsequent filings. As always with 13D/G disclosures, stakes reflect the most recent filing and a holder dropping below 5% may not file again.
Earnings history adds a layer of caution. The last two prints both moved the stock sharply lower on the day — down 8% in August after the Q2 report, and down 6.7% the prior quarter. The five-day reactions were also negative. The next print is scheduled for November 10. With the stock up 20% this week and sitting well above where shorts initiated, the setup into that event matters: whether the AI infrastructure narrative starts generating hard revenue figures, and whether execution on the Kentucky site can close the gap between the $33.85 consensus target and a stock trading at $17.33, will likely determine whether the current short base covers or adds.
See the live data behind this article on ORTEX.
Open WULF on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
